<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04093050</url>
  </required_header>
  <id_info>
    <org_study_id>PS4229-101</org_study_id>
    <nct_id>NCT04093050</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics of Vasopressin in Healthy Volunteers</brief_title>
  <official_title>A Phase 1, Open-Label, Two-Arm, Parallel-Group, Pharmacokinetic Study on Plasma Clearance of Vasopressin in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Endo Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Endo Pharmaceuticals</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open-label Phase I pharmacokinetic (PK) study of Vasostrict® (vasopressin injection, USP) in&#xD;
      healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 10, 2019</start_date>
  <completion_date type="Actual">April 11, 2021</completion_date>
  <primary_completion_date type="Actual">April 8, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma Clearance of vasopressin following IV administration in participants with TT genotype versus AA/AT genotype</measure>
    <time_frame>15 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Healthy Volunteer Safety Study</condition>
  <arm_group>
    <arm_group_label>TT Genotype</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AA/AT Genotype</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vasostrict Injectable Product</intervention_name>
    <description>Vasostrict® (vasopressin injection, USP)</description>
    <arm_group_label>AA/AT Genotype</arm_group_label>
    <arm_group_label>TT Genotype</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed the informed consent form (ICF) approved by an institutional review board&#xD;
             (IRB).&#xD;
&#xD;
          2. Determined to have genotype TT, AA, or AT.&#xD;
&#xD;
          3. Weighs at least 50 kg and not more than 100 kg.&#xD;
&#xD;
          4. If female, must be surgically sterile for at least 6 months prior to screening,&#xD;
             post-menopausal for at least 1 year, using adequate contraception, have a vasectomized&#xD;
             partner or abstinent.&#xD;
&#xD;
          5. Participant is in good physical health as determined by the investigator, based on&#xD;
             physical examination, medical history, 12-lead ECG, vital signs, and clinical&#xD;
             laboratory tests.&#xD;
&#xD;
          6. Participant is willing and able to comply with all aspects of the protocol, including&#xD;
             the diet and medication restrictions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. If female, breastfeeding or pregnant.&#xD;
&#xD;
          2. Use of any prescription or over-the-counter drugs.&#xD;
&#xD;
          3. Clinical laboratory test results outside laboratory normal range that are determined&#xD;
             by the investigator to be clinically significant.&#xD;
&#xD;
          4. Creatinine clearance &lt;90 mL/min (estimated by Cockcroft-Gault formula).&#xD;
&#xD;
          5. Pulse rate ≤50 or ≥100 bpm, systolic blood pressure ≤90 or ≥140 mmHg, diastolic blood&#xD;
             pressure ≤60 or ≥90 mmHg or a history of hypertension, recurrent hypotensive events,&#xD;
             or known orthostatic hypotension.&#xD;
&#xD;
          6. ECG abnormalities (PR &gt;200 msec; QRS complex &gt;120 msec; QT interval corrected for&#xD;
             heart rate using Fridericia's formula [QTcF] interval &gt;450 msec if male and &gt;470 msec&#xD;
             if female, or history of clinically significant ECG abnormalities (such as cardiac&#xD;
             arrhythmia, familial long QT syndrome, or previous torsade de pointes).&#xD;
&#xD;
          7. History of diabetes insipidus, syndrome of inappropriate antidiuretic hormone&#xD;
             secretion, or any other disorder associated with fluid or sodium imbalance.&#xD;
&#xD;
          8. History or evidence of any clinically significant surgical or medical condition (eg,&#xD;
             cardiovascular, gastrointestinal, endocrine, hematologic, hepatic, immunologic,&#xD;
             metabolic, urologic, pulmonary, neurologic, psychiatric, dermatologic, renal, and/or&#xD;
             another major disease or malignancy) that would be anticipated, in the opinion of the&#xD;
             investigator, to compromise participant safety or PK evaluation.&#xD;
&#xD;
          9. Known allergy or hypersensitivity to 8-L-arginine vasopressin or chlorobutanol.&#xD;
&#xD;
         10. Clinically significant history of allergic conditions (including drug allergies,&#xD;
             asthma, eczema, or anaphylactic reactions, but excluding untreated, asymptomatic&#xD;
             seasonal allergies), as judged by the investigator.&#xD;
&#xD;
         11. History of or current infection with hepatitis B virus, hepatitis C virus, or human&#xD;
             immunodeficiency virus.&#xD;
&#xD;
         12. Use of tobacco- or nicotine-containing products in the 6 months prior or intent to&#xD;
             smoke during the study. Smoking status will be confirmed by negative urine cotinine&#xD;
             test.&#xD;
&#xD;
         13. Consumption of more than 21 units (males) or more than 14 units (females) of alcohol&#xD;
             per week (1 unit = 10 g pure alcohol or 250 mL of beer [5%], 35 mL of spirits [35%],&#xD;
             or 100 mL of wine [12%]). Alcohol use is prohibited from 72 hours prior to admission&#xD;
             on Day -2 until discharge from clinical unit.&#xD;
&#xD;
         14. History of chronic drug or alcohol abuse in the last 4 years. Lack of abuse will be&#xD;
             confirmed by urine screens for alcohol and drugs of abuse (amphetamines, barbiturates,&#xD;
             benzodiazepines, cannabinoids, cocaine metabolites, methamphetamines,&#xD;
             methylenedioxymethamphetamine, and opiates [including heroin, codeine, and&#xD;
             oxycodone]).&#xD;
&#xD;
         15. Participation in a clinical trial of an investigational drug within the 30 days prior&#xD;
             to admission on Day -2.&#xD;
&#xD;
         16. Significant blood loss or donation (≥500 mL within the 30 days prior to admission on&#xD;
             Day -2).&#xD;
&#xD;
         17. Is an employee or the close relative of an employee of the sponsor or clinical unit.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shannon Dalton</last_name>
    <role>Study Director</role>
    <affiliation>Endo Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #2</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #1</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 16, 2019</study_first_submitted>
  <study_first_submitted_qc>September 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2019</study_first_posted>
  <last_update_submitted>May 17, 2021</last_update_submitted>
  <last_update_submitted_qc>May 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vasopressins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

